Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary T Ferguson

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Journal of Asthma and Allergy|April 20, 2018
Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthmaGary T Ferguson, Adel H Mansur, Joshua S Jacobs, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 13, 2021
TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory FlowDonald A Mahler, Andrea Ludwig-Sengpiel, Gary T Ferguson, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 26, 2018
Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN StudiesGary T Ferguson, Edward M Kerwin, James F Donohue, et al.
Respiratory Medicine|September 1, 2015
Tiotropium + olodaterol shows clinically meaningful improvements in quality of lifeDave Singh, Gary T Ferguson, Josef Bolitschek, et al.
Respiratory Medicine|September 29, 2018
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trialsGary T Ferguson, Roland Buhl, Ulrich Bothner, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 26, 2019
Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthmaGeoffrey Chupp, Njira L Lugogo, Joel N Kline, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 8, 2023
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation HistorySanjay Sethi, Brendan Clark, Lindsay G S Bengtson, et al.
Clinical Drug Investigation|October 3, 2013
ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsStephen I Rennard, Paul D Scanlon, Gary T Ferguson, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 12, 2019
Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical TrialsGary T Ferguson, Gregory Feldman, Krishna K Pudi, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|January 23, 2018
Recruiting Patients After Hospital Discharge for Acute Exacerbation of COPD: Challenges and Lessons LearnedGary T Ferguson, Bonnie Beck, Emmanuelle Clerisme-Beaty, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Journal of Asthma and Allergy|April 20, 2018
Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthmaGary T Ferguson, Adel H Mansur, Joshua S Jacobs, et al.
International Journal of Chronic Obstructive Pulmonary Disease|September 13, 2021
TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory FlowDonald A Mahler, Andrea Ludwig-Sengpiel, Gary T Ferguson, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 26, 2018
Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN StudiesGary T Ferguson, Edward M Kerwin, James F Donohue, et al.
Respiratory Medicine|September 1, 2015
Tiotropium + olodaterol shows clinically meaningful improvements in quality of lifeDave Singh, Gary T Ferguson, Josef Bolitschek, et al.
Respiratory Medicine|September 29, 2018
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trialsGary T Ferguson, Roland Buhl, Ulrich Bothner, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 26, 2019
Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthmaGeoffrey Chupp, Njira L Lugogo, Joel N Kline, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 8, 2023
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation HistorySanjay Sethi, Brendan Clark, Lindsay G S Bengtson, et al.
Clinical Drug Investigation|October 3, 2013
ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsStephen I Rennard, Paul D Scanlon, Gary T Ferguson, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 12, 2019
Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical TrialsGary T Ferguson, Gregory Feldman, Krishna K Pudi, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|January 23, 2018
Recruiting Patients After Hospital Discharge for Acute Exacerbation of COPD: Challenges and Lessons LearnedGary T Ferguson, Bonnie Beck, Emmanuelle Clerisme-Beaty, et al.
Pageof 11